Document is current
Any future updates will be listed below
-
Authors
Pongracz, Tamas https://orcid.org/0000-0002-8089-4352
Biewenga, Maaike https://orcid.org/0000-0002-2797-6164
Stoelinga, Anna Eva Charlotte https://orcid.org/0000-0002-3110-924X
Bladergroen, Marco René https://orcid.org/0000-0003-4434-4799
Nicolardi, Simone https://orcid.org/0000-0001-8393-1625
Trouw, Leendert Adrianus https://orcid.org/0000-0001-5186-2290
Wuhrer, Manfred https://orcid.org/0000-0002-0814-4995
de Haan, Noortje https://orcid.org/0000-0001-7026-6750
van Hoek, Bart https://orcid.org/0000-0001-6527-764X
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (721815)
Zambon Pharma (Zambon Pharma)
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 5 April 2024
First Online: 14 May 2024
Declarations
:
: The study protocol was approved a priori by the local ethical committee (B19.071). Informed consent was obtained from all patients and healthy controls. The study complied with the latest version of the Declaration of Helsinki.
: All authors agreed to the publication of this study.
: M. Wuhrer is inventor on several patents on derivatizing sialic acids for high-throughput glycosylation profiling. The other authors declare that they have no conflicts of interest.
